Brain abscess

Brain abscess: recognition and emergency referral from AU general practice

By Dr HB Lo, FACRRM 9 min read

Brain abscess is a focal pyogenic infection of brain parenchyma — rare, but carrying 10–20% mortality and neurological sequelae in ~30% of survivors.

The classic triad of headache, fever, and focal deficit is present in fewer than 20% of cases. Headache alone — new or progressive — is the most consistent symptom. Any patient with sinusitis, otitis, dental sepsis, or endocarditis alongside a new headache warrants urgent contrast MRI and emergency referral.

Lumbar puncture is contraindicated with mass effect. Empirical treatment is ceftriaxone plus metronidazole; surgical aspiration is standard for lesions ≥2.5 cm.

Brain abscess — a focal collection of pus within brain parenchyma — is rare but carries consequences out of proportion to its incidence. Australian annual incidence is approximately 0.4–0.9 per 100,000, a rate that has been rising over two decades as immunocompromised populations expand and neuroimaging improves detection. Mortality with modern care is 10–20%, and long-term neurological sequelae — focal deficit, post-abscess epilepsy, cognitive change — affect approximately 30% of survivors (Brouwer et al., NEJM 2014; Bodilsen et al., Clin Microbiol Infect 2020).

The central challenge for general practitioners is that brain abscess rarely presents with the classic textbook picture. The triad of headache, fever, and focal neurological deficit is present in fewer than 20% of cases. Headache alone is the most consistent feature, occurring in roughly 70% of patients. The implication is straightforward: in any patient with a predisposing source for intracranial infection plus a new, progressive, or nocturnal headache, brain abscess must be included in the differential and investigated urgently — even in the absence of fever or focal signs.

A. Core clinical — the AU general-practice framework

Sources and microbiology

Understanding the source of brain abscess guides both the empirical antibiotic choice and the need for source-control surgery or ENT referral.

Contiguous spread (~45–50%) accounts for the largest group:

  • Frontal or ethmoidal sinusitis (~25%) → frontal lobe abscess via direct extension through thinned orbital plate or via valveless emissary veins.
  • Otitis media / mastoiditis (~15%) → temporal lobe or cerebellar abscess.
  • Dental sepsis or periodontal disease (~10%) → frontal or temporal lobe, often with anaerobic organisms.

Haematogenous spread (~25%): infective endocarditis is the most important cause and produces multiple abscesses at the grey-white junction in MCA territory. Pulmonary suppuration (bronchiectasis, lung abscess, empyema), intravenous drug use, and congenital cyanotic heart disease (right-to-left shunt bypassing pulmonary filter) complete this group. Hereditary haemorrhagic telangiectasia (HHT) with pulmonary arteriovenous malformations produces the same physiology — recurrent brain abscess in a patient without obvious immunocompromise should prompt investigation for HHT.

Direct inoculation (~10%): post-craniotomy (3–8% rate in modern series), penetrating head injury, or intracranial hardware (shunt, DBS electrode, baclofen pump).

Cryptogenic (~15%): no source identified despite thorough workup.

Microbiology: eTG and the IDSA guideline (Tunkel et al.) identify Streptococcus spp. (particularly the S. anginosus / “milleri” group) as the dominant organism in approximately 70% of community-acquired abscess. S. aureus predominates in post-traumatic, post-neurosurgical, and endocarditis-related cases; MRSA is a consideration in healthcare-associated infection. Anaerobes (Bacteroides, Prevotella, Fusobacterium) are present in about one-third of cases overall, usually in polymicrobial infections from dental or sinus sources. Immunocompromised patients require broader consideration including Nocardia (transplant, anti-TNF therapy), Toxoplasma (HIV CD4 <100), and Aspergillus or Mucorales (haematological malignancy, prolonged neutropenia).

Clinical presentation — what to look for

Per Brouwer et al. (NEJM 2014), the evolution is typically subacute over days to weeks, not hours:

  • Headache (~70%) — new-onset, progressive, often worsening overnight or with Valsalva manoeuvre; may be localised to the side of the abscess.
  • Fever (~50%) — often low-grade; absent in approximately half of cases once the abscess has encapsulated; absence does not exclude infection.
  • Focal neurological deficit (~50%) — hemiparesis, dysphasia, visual field defect, cerebellar signs, cranial nerve palsy; determined by abscess location.
  • Seizures (~25%) — focal or generalised; can be the presenting feature without other symptoms.
  • Altered mental state or behavioural change (~30–50%) — lethargy, confusion, frontal apathy, personality change.
  • Nausea and vomiting from raised intracranial pressure.

Meningism is typically absent unless intraventricular rupture has occurred — a catastrophic complication with mortality >80%.

The predisposing source history

Active case-finding during history-taking significantly improves recognition:

  • Recent or ongoing sinusitis, otitis media or mastoiditis, dental infection, or recent dental procedure.
  • Known endocarditis, valve prosthesis, or IVDU.
  • Congenital cyanotic heart disease (unrepaired or palliated).
  • Pulmonary bronchiectasis, lung abscess, or empyema.
  • Recent neurosurgery, penetrating head trauma, or open skull fracture.
  • Immunocompromise — HIV, solid organ transplant, haematological malignancy, JAK inhibitors, anti-TNF biologics, high-dose corticosteroids, advanced diabetes.
  • Travel — neurocysticercosis (endemic regions) and melioidosis (Top End Australia, Southeast Asia) are important in the Australian context.

Examination

Vital signs, GCS, and cognitive assessment come first. Cushing’s reflex — the triad of bradycardia, hypertension, and irregular breathing — signals impending herniation and requires immediate emergency care (call 000). Focal neurological examination should be documented systematically: pyramidal signs (upper motor neurone pattern hemiparesis, hyperreflexia, Babinski), dysphasia, visual field defect, cerebellar dysfunction (ataxia, dysmetria in posterior fossa abscess), and cranial nerve deficits. Papilloedema, present in ~25% of cases, requires days to develop; its absence does not exclude raised ICP. ENT examination — otoscopy for otitis/cholesteatoma, sinus tenderness, and oral cavity inspection for dental disease — is essential to identify a contiguous source. Cardiac examination — murmur, peripheral stigmata of endocarditis (splinter haemorrhages, Janeway lesions, Osler nodes) — evaluates for haematogenous seeding.

B. Imaging — the gold standard

MRI brain with gadolinium and DWI

Gadolinium-enhanced MRI brain (MBS item 63007) is the gold standard. The combination of ring enhancement around a central cavity plus restricted diffusion on DWI (high DWI signal, low ADC values) is highly specific for pyogenic abscess and discriminates it from the more common cystic or necrotic tumour, which typically shows facilitated diffusion within the necrotic core (Brouwer NEJM 2014). MR spectroscopy — elevated amino acids, lactate, and acetate within the cavity — provides additional confirmation when the imaging pattern is equivocal.

CT brain with contrast (MBS items 56007 / 56022) is a reasonable initial alternative if MRI is unavailable — it shows a ring-enhancing hypodense lesion with surrounding oedema — but it is less sensitive for early cerebritis, small lesions, and posterior fossa disease. If CT raises concern, proceed to MRI.

Lumbar puncture is contraindicated

eTG and the IDSA guideline are unequivocal: lumbar puncture is contraindicated in the presence of significant mass effect, midline shift, posterior fossa lesion, or raised ICP. Brain abscess produces substantial surrounding oedema; LP in this context risks fatal cerebellar tonsillar herniation. CSF analysis is also generally unhelpful — findings are non-specific and the causative organism is rarely grown from CSF in established abscess. The definitive microbiological diagnosis comes from stereotactic aspiration of the abscess itself.

C. Antibiotic management

Empirical regimen

Per Therapeutic Guidelines (eTG) and IDSA 2017 (Tunkel et al.):

Community-acquired, immunocompetent (sinus/otic/dental/cryptogenic source):

  • Ceftriaxone 2 g IV twice daily + metronidazole 500 mg IV 8-hourly

Post-neurosurgical, post-traumatic, IE, or suspected MRSA: add vancomycin (weight-based, targeting AUC₂₄ 400–600 mg·h/L per AMH and SHPA guidelines).

Gram-negative / Pseudomonas risk (post-neurosurgical, otomastoid, immunocompromised): substitute meropenem 2 g IV 8-hourly for ceftriaxone.

Immunocompromised — broaden empirically: add anti-Toxoplasma cover (HIV, CD4 <100 — sulfadiazine + pyrimethamine + folinic acid, or TMP-SMX); add voriconazole for suspected Aspergillus; add liposomal amphotericin B for Mucorales.

Blood cultures should be taken before antibiotics. Avoid commencing antibiotics in the GP surgery unless transfer will be delayed beyond 60 minutes and the patient meets sepsis criteria — early antibiotic administration reduces the yield of stereotactic aspiration cultures.

Duration and oral switch

Traditional treatment duration is 6–8 weeks of IV antibiotics, extended to 8–12 weeks for post-neurosurgical, immunocompromised, or fungal abscess. The ESCMID brain abscess guideline (Bodilsen 2024) supports early oral switch at 2–3 weeks in clinically stable patients with susceptible organisms and adequate oral bioavailability (metronidazole, moxifloxacin, linezolid, TMP-SMX, rifampicin). Hospital in the Home (HITH) programmes enable completion of IV therapy at home under GP shared care.

D. Australian operations

Surgical management

Neurosurgical referral is mandatory for all confirmed or suspected brain abscesses. Stereotactic aspiration is preferred for lesions ≥2.5 cm — it is both diagnostic (providing pus for culture and sensitivities) and therapeutic (reducing mass effect), and can be repeated if needed (Tunkel IDSA 2017). Open craniotomy and excision is reserved for multiloculated abscesses, posterior fossa abscess with hydrocephalus, traumatic abscesses with retained foreign material, fungal abscess (where capsule resistance to antifungal penetration necessitates surgical removal), and failure of repeated aspiration. Medical management alone (antibiotics without surgery) is appropriate for cerebritis (the pre-capsulation phase, where the lesion is ill-defined on imaging) or for small lesions (<2.5 cm) in clinically stable patients.

Source control

Contiguous sinus or otic disease requires ENT referral for drainage of the primary focus; simultaneous control of the source substantially improves outcomes and reduces recurrence. Endocarditis requires cardiology and cardiothoracic surgery referral. Dental sepsis requires maxillofacial or dental referral for extraction and periodontal management.

GP shared-care post-discharge

Chronic disease management items (GPCCMP MBS items 965/967) support the post-discharge period. Monitor for antibiotic side effects (C. difficile with broad-spectrum long-term therapy, renal function with vancomycin, cytopenias and peripheral neuropathy with linezolid >2 weeks). Detect and manage post-abscess epilepsy — present in ~30% of survivors, often requiring long-term antiepileptic medication and imposing Austroads driving restrictions: patients must be seizure-free for 6 months before driving a private vehicle after a first unprovoked seizure. Neuropsychological rehabilitation may be required for cognitive sequelae.

E. Special populations

Children. Paediatric brain abscess follows the same principles. Congenital cyanotic heart disease — tetralogy of Fallot, transposition, other right-to-left shunts — is the dominant predisposing factor in children under 5 years. Otogenic abscess predominates in older children. Outcomes are broadly similar to adults with equivalent treatment.

Immunocompromised patients. HIV with CD4 <100 requires empirical anti-Toxoplasma therapy (the commonest cause of ring-enhancing lesions in this group); the standard approach is a 2-week clinical and radiological trial of anti-Toxoplasma therapy before biopsy unless the patient is deteriorating or the lesion fails to improve. Solid organ transplant recipients are at risk from Nocardia and Aspergillus; haematological malignancy with prolonged neutropenia significantly raises Mucorales risk.

Post-neurosurgical. Hospital-acquired brain abscess following craniotomy or intracranial device placement typically involves healthcare-associated organisms including MRSA and Gram-negative bacilli; empirical vancomycin plus meropenem is appropriate pending cultures.

Spinal epidural abscess (ICD-10 G06.1) is a related emergency presenting with back pain, fever, and progressive neurological deficit including lower limb weakness and sphincter disturbance. Haematogenous seeding from S. aureus bacteraemia is the most common cause. Emergency MRI spine and urgent neurosurgical referral follow the same logic as for brain abscess.

When to escalate

A patient with any predisposing source for intracranial infection plus a new or progressive headache — with or without fever or focal deficit — warrants same-day urgent contrast MRI brain and emergency department referral. Do not perform a lumbar puncture before imaging. A toxic-appearing patient with GCS decline, Cushing’s reflex, or rapid deterioration requires Cat-1 ambulance (call 000). Do not commence empirical antibiotics in the surgery unless transfer will be substantially delayed (>60 minutes) and the patient is septic. Once imaging confirms abscess, neurosurgical review is required on the same day regardless of clinical stability.

What this article is and is not

This is general health information drawn from current Australian and international guidelines — Therapeutic Guidelines (eTG), the IDSA brain abscess guideline, ESCMID 2024, and Austroads Fitness to Drive standards — and major clinical cohort studies. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about antibiotic regimen, surgical management, and rehabilitation are made by the treating GP, neurologist, neurosurgeon, and infectious diseases specialist.

For Australian consumer-facing information: HealthDirect — brain abscess, Better Health Channel — brain abscess.

For emergency: call 000 for any acute neurological deterioration.

Sources cited

  1. Therapeutic Guidelines (eTG complete) — Antibiotic: brain abscess
  2. IDSA — Tunkel et al. CID 2017 brain abscess guideline
  3. ESCMID — Bodilsen 2024 brain abscess guideline
  4. Brouwer et al. — Brain Abscess (NEJM 2014)
  5. Bodilsen et al. — Danish brain abscess cohort (Clin Microbiol Infect 2020)
  6. Austroads — Assessing Fitness to Drive
  7. HealthDirect — brain abscess
  8. Better Health Channel — brain abscess

Frequently asked questions

  • What causes brain abscess?

    Approximately half of brain abscesses arise from contiguous spread of infection — sinusitis (~25%, especially frontal sinus to frontal lobe), otitis media or mastoiditis (~15%, to temporal lobe or cerebellum), and dental sepsis or periodontal infection (~10%). About 25% arise from haematogenous seeding, most importantly from infective endocarditis, pulmonary abscess or empyema, intravenous drug use, and congenital cyanotic heart disease with right-to-left shunting (which bypasses the pulmonary filter). About 10% follow direct inoculation — post-craniotomy, penetrating head injury, or intracranial monitoring devices. In roughly 15% no source is found. In immunocompromised patients — HIV, solid organ transplant, haematological malignancy, biologics — atypical organisms including Toxoplasma, Nocardia, Aspergillus, and Cryptococcus account for a significant proportion.

  • Why is the classic triad unreliable?

    The triad of headache, fever, and focal neurological deficit is present in fewer than 20% of brain abscess cases. Headache occurs in roughly 70%, fever in only about 50% (often low-grade or absent once the abscess is encapsulated), and focal deficit in around 50%. Seizures present as the first symptom in about 25%. Meningism is usually absent unless there has been intraventricular rupture. This means relying on the classic triad leads to missed diagnosis. Any patient with a predisposing source plus a new, progressive, or nocturnal headache — even without fever or focal signs — should be investigated urgently. In immunocompromised patients, the presentation may be even more subtle.

  • When is lumbar puncture contraindicated in suspected brain abscess?

    Lumbar puncture is contraindicated when there is significant mass effect, midline shift, posterior fossa lesion, or any clinical or radiological features suggesting raised intracranial pressure or impending herniation. Brain abscess typically produces substantial surrounding oedema and mass effect; LP in this context risks cerebellar tonsillar herniation, which is rapidly fatal. LP is also generally unhelpful — CSF is normal or shows non-specific inflammation in most cases and does not yield the causative organism. Contrast CT or MRI brain should be performed before any lumbar puncture when brain abscess, mass lesion, or raised ICP is considered.

  • How is brain abscess distinguished from brain tumour on imaging?

    The gold standard is gadolinium-enhanced MRI brain with diffusion-weighted imaging (DWI). Brain abscess typically shows a ring-enhancing lesion with central diffusion restriction (low ADC values) on DWI — the pus within the cavity restricts water movement. High-grade glioma and necrotic metastasis, by contrast, typically show facilitated diffusion (high ADC) within the necrotic centre. MR spectroscopy can support the diagnosis — elevated amino acids, lactate, and acetate are characteristic of pyogenic abscess. CT with contrast is an acceptable alternative if MRI is unavailable, showing a ring-enhancing low-density lesion with surrounding oedema, though it is less sensitive for early cerebritis, small lesions, and posterior fossa disease.

  • What antibiotic regimen is used for brain abscess?

    Per Therapeutic Guidelines and IDSA guidelines, empirical treatment for community-acquired brain abscess in an immunocompetent patient is ceftriaxone 2 g IV twice daily plus metronidazole 500 mg IV 8-hourly. Vancomycin is added for post-neurosurgical infection, penetrating trauma, suspected MRSA, or endocarditis as the source. Meropenem 2 g IV 8-hourly is used when Gram-negative organisms or Pseudomonas are likely (post-neurosurgical, otomastoid source, immunocompromised). Immunocompromised patients require broadened cover including antifungal agents, and empirical anti-Toxoplasma therapy (sulfadiazine plus pyrimethamine, or TMP-SMX) when HIV CD4 count is below 100. Traditional treatment duration is 6–8 weeks IV; early oral switch at 2–3 weeks is emerging as non-inferior in stable patients with susceptible organisms.

  • What are the long-term consequences of brain abscess?

    Mortality with modern care is 10–20%, higher in immunocompromised patients, those with delayed diagnosis, and fungal abscess. Of survivors, roughly 30% have long-term sequelae: focal motor deficit, post-abscess epilepsy (lifetime risk of approximately 30%, often requiring long-term antiepileptic therapy), and cognitive or behavioural change depending on lesion location. Post-abscess epilepsy imposes Australian driving restrictions — patients must be seizure-free for 6 months before driving a private vehicle, per Austroads guidelines. The source of infection must be eradicated (dental, ENT, cardiac) or recurrence rates are high. Rehabilitation through neurological occupational therapy, physiotherapy, and neuropsychology may be needed, coordinated through a GPMP.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.